The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a huge mover today! About 590,465 shares traded hands. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 43.75% since April 5, 2016 and is uptrending. It has outperformed by 41.79% the S&P500.
The move comes after 5 months positive chart setup for the $322.67 million company. It was reported on Nov, 7 by Barchart.com. We have $6.19 PT which if reached, will make NASDAQ:BCRX worth $132.29M more.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage
Out of 8 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. BioCryst Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Friday, August 12 by Piperjaffray. The rating was downgraded by JP Morgan on Tuesday, February 9 to “Neutral”. The firm earned “Neutral” rating on Friday, October 9 by Bank of America. On Wednesday, January 6 the stock rating was upgraded by Jefferies to “Buy”. The rating was upgraded by PiperJaffray on Friday, August 12 to “Overweight”. The firm has “Underperform” rating by Bank of America given on Wednesday, November 11. As per Wednesday, September 9, the company rating was initiated by Jefferies. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by Jefferies on Tuesday, February 9. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by Rodman & Renshaw on Tuesday, February 9. The company was upgraded on Friday, August 7 by Zacks.
According to Zacks Investment Research, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in 2016 Q2. Its down 0.31, from 1.1 in 2016Q1. The ratio is negative, as 17 funds sold all BioCryst Pharmaceuticals, Inc. shares owned while 31 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 45.48 million shares or 10.25% less from 50.68 million shares in 2016Q1.
Rtw Limited Com has invested 2.17% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Alliancebernstein L P holds 0% or 136,020 shares in its portfolio. Savings Bank Of New York Mellon, a New York-based fund reported 306,563 shares. The Texas-based Teacher Retirement Systems Of Texas has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Department Mb Comml Bank N A accumulated 0.01% or 5,225 shares. Blackrock Fund Advsr holds 2.85M shares or 0% of its portfolio. Moreover, Blackrock Invest Mngmt Limited Liability Corporation has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 278,020 shares. Natl Planning Corporation accumulated 41,000 shares or 0.01% of the stock. Credit Suisse Ag last reported 129,571 shares in the company. D E Shaw And Company reported 3.43 million shares or 0.02% of all its holdings. Connor Clark Lunn Inv Management has 0% invested in the company for 133,005 shares. Cornerstone Capital Mngmt Holding Ltd Liability Company has 55,500 shares for 0% of their US portfolio. Wells Fargo And Communication Mn accumulated 21,830 shares or 0% of the stock. Kcg Inc holds 10,511 shares or 0% of its portfolio. Commonwealth Equity Services has 0% invested in the company for 40,255 shares.
Insider Transactions: Since August 9, 2016, the stock had 0 buys, and 5 selling transactions for $20.50 million net activity. 5,864 shares were sold by STAAB THOMAS R II, worth $30,388. Another trade for 30,000 shares valued at $121,800 was sold by Babu Yarlagadda S. 4.05M shares were sold by BAKER BROS. ADVISORS LP, worth $20.25M. Barnes Alane P also sold $35,684 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Wednesday, September 14.
More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Fool.com, which released: “Here’s the Buzz Behind BioCryst Pharmaceuticals, Inc.’s 27% Gain in July” on August 11, 2016. Seekingalpha.com‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results …” and published on August 05, 2016 is yet another important article.
BCRX Company Profile
BioCryst Pharmaceuticals, Inc. (BioCryst), incorporated on November 15, 1991, is a biotechnology company. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Firm focuses on the treatment of rare diseases. The Firm uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.